They were much higher previously yes, however if we could raise enough from Hervaxx/PD1-VAXX sales we may not see another dreaded CR again.I would love to see an update on both of the B Cell trials that are ongoing.
Right now the aim is to be better than the previous best in market drug Herceptin (for Hervaxx).
7.5 months doesn't seem like a big target to reach. If there is a 25-40% increase in progression free survival to say 9.5 months/10.5 months, I feel with the patent expired for Herceptin and Hervaxx expiring in 2036 there may be some benefit for a Hervaxx sale to a potential buyer.
I think US $250-500million is reasonable with a potential for a small percentage in ongoing royalties.
Anything to avoid the share confetti cannon from coming out of storage is a bonus in my eyes.
They were much higher previously yes, however if we could raise...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.001(1.67%) |
Mkt cap ! $446.5M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.3¢ | 5.8¢ | $1.661M | 27.74M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 513999 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 51941 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.2¢ |
Change
0.001 ( 4.38 %) |
||||
| Open | High | Low | Volume | ||
| 6.0¢ | 6.2¢ | 5.8¢ | 10422066 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| IMU (ASX) Chart |